Industry
The €8.5 Billion Defense: Dutch Innovative Pharma Fights Back Against Cost-Control Policies
The Dutch Association for Innovative Medicines (VIG) releases a detailed report highlighting the sector\'s €8.5 billion gross added value, warning that cost-containment measures threaten patient access, clinical trials, and Europe\'s biopharma sovereignty.
3 hrs ago